Advancing the World of Health

Please be aware of potentially fraudulent job postings on other websites or suspicious recruiting email or text messages that attempt to collect your confidential information. Email AddressWe’ll send job alerts and updates here Create a job alert to be notified when positions that match your skills and location become available. Sign up to get the latest company news, events, and future opportunities straight to your inbox. At BD, your ideas, curiosity and purpose can makea global impact In December 2025, BD was sued by Tela Bio Inc., makers of a ovine forestomach matrix hernia mesh, who alleged that BD engaged in anticompetitive practices to push Tela out of the market for surgical meshes while raising prices for providers and patients.

The name “embecta” represents the company’s commitment to people living with diabetes and its corporate heritage, with the “em-” prefix evoking empathy for people living with diabetes and the empowerment of the new company and the “bect” imbibed from Becton. Embecta Corporation is a standalone public company focused on diabetes care. BD can help you improve surgical outcomes and lower costs Surgical efficiency, patient safety and outcomes, procedural cost management BD can help you identify potential “at-risk” patients, empower clinical intervention, and advance health system insights BD can help you optimize clinical effectiveness to help drive improvement in patient outcomes

Business segments

1925 BD acquired the Yale™ Luer-Lok™ — the first simple, secure method for attaching and removing a needle from a syringe. 1954 Production of the first disposable syringes to be used in the Salk Polio vaccine trial takes place. 1988 BD launched the first safety engineered syringe.

• In April 2016, the Occupational Safety and Health Administration fined BD US$112,700 for safety violations.
• Our Purpose drives us to create innovative solutions that make a meaningful impact on advancing the world of health™.
• BD stated that the use of the affected devices may cause an air embolism or leakage of blood and/or therapy, which may result in serious injury or death.
• 2017 The first clinical lab application of artificial intelligence and robotics to automatically report and release negative urine cultures is utilized.\r\n

BD Completes Combination of Biosciences & Diagnostic Solutions Business with Waters Corporation

R. Bard, a medical device https://jaya9betting.com/ company founded in 1907 in Covington, Georgia. BD and its affiliates and subsidiaries (BD) do not accept any liability for fees for resumes from recruiters or employment agencies (“Agency”), without a binding, written recruitment agreement between BD and Agency describing the services and specific job openings (“Agreement”). They found repeat and serious violations of health and safety law that had resulted in two employees having partial finger amputations.

BD recalled and tested the syringes in question, and revealed sterile particulates in 0.013 percent of the products. Bard, Inc. and its parent company BD were fined $60 million USD for failing to adequately inform patients about health risks related to their transvaginal mesh devices. Becton, Dickinson and Company (BD; also Becton Dickinson or Becton) is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. With a focus on quality, reliability, and continuous innovation, the Medical Essentials segment is driving better outcomes across the care continuum. 1906 BD opened the first syringe and needle factory in the United States.

2015 BD became the first to integrate IV pumps with electronic health records.\r\n 2017 The first clinical lab application of artificial intelligence and robotics to automatically report and release negative urine cultures is utilized.\r\n 2019 BD launched the first venous stent to treat iliofemoral venous occlusive disease.\r\n 2020 BD launched the first sample preparation and flow cytometry system to enable clinical laboratories to fully automate the sample-to-answer process. 2021 BD launched the first ready-to-use aqueous povidone-iodine (PVP-I) surgical irrigation solution. Bard might be a scam, please verify by searching for the posting on the careers page or contact us at

Pfitzer et al. (2013) identify BD’s development of a needleless injection system as an example of leading businesses’ role in creating shared value. The company’s line of plastic conical screwtop test tubes, known as ‘Falcon tubes’, is popular and the term is sometimes used as a generic term for such tubes. In certain places, BD Medical also offers consulting and analytics related services. In 2024, BD announced it would acquire Edwards Lifesciences’ critical care unit for $4.2 billion. In July 2021, BD announced it would acquire surgical scaffold maker Tepha, after having acquired Velano Vascular earlier the same month. This agreement protects patents and intellectual properties of both companies ensuring the quality and integrity of Embecta Corporation’s cannulas used in their products.

1987 BD built a plant to manufacture diagnostic products in Fukushima, Japan. 1999 The world’s shortest, thinnest insulin pen needle is introduced. 2007 BD AutoShield™ needle is launched.

The transaction was completed later that year, and the company became a wholly-owned subsidiary of BD, rebranded as Bard. In October 2014, the company agreed to acquire CareFusion for a price of US$12.2 billion in cash and stock. Later Retractable would claim BD was falsely advertising its own brand of retractable needle as the “world’s sharpest needle”. Retractable would accuse BD of patent infringement after BD released a retractable needle of its own. The company was founded in 1897 in New York City by Maxwell Becton and Fairleigh S. Dickinson. We know that possibilities are endless when people feel supported and inspired.

Food and Drug Administration and worldwide health agencies to coordinate recall activities. The approximately 2.8 million BD Q-Syte and 2.9 million BD Nexiva units containing 5 million BD Q-Syte devices that were recalled were distributed in the United States, Asia, Canada, Europe, Mexico, the Middle East, South Africa, and South America. BD stated that the use of the affected devices may cause an air embolism or leakage of blood and/or therapy, which may result in serious injury or death. In April 2016, the Occupational Safety and Health Administration fined BD US$112,700 for safety violations.